FDA Delays Nonprescription Drug Rule in Trump’s Regulation Pause

The FDA is delaying the implementation of a final rule outlining how manufacturers can market their drugs that don’t need a prescription.

The final rule, which was set with an effective date of Jan. 27, is now delayed until March 21, according to the Food and Drug Administration’s notice published Friday in the Federal Register. The pause follows President Donald Trump’s Jan. 20 executive order to freeze pending regulatory actions.

The FDA rule established requirements for manufacturers seeking to market drugs that don’t need a prescription, which would expand the development of such products and increase consumer access to ...